-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

Benzinga·10/30/2026 18:08:09
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.